A synthetic pentapeptide corresponding to sequence 43-47 of human fibrinogen B beta chain elicited, in rabbits, antibodies that during immunoblotting recognized intact fibrinogen, fragments X and Y as well as the B beta chain. Since fragment Y is the last peptide product which reacts with anti-beta 43-47 antibodies, splitting of fragment Y into fragment D and fragment E must be accompanied by plasmin cleavage of the peptide bond beta Lys-47-Ala-48.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/0304-4165(86)90212-6 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A mathematical model of plasmin-mediated fibrinolysis of single fibrin fibers.
PLoS Comput Biol
December 2024
Department of Mathematics and Statistics, University of Central Oklahoma, Edmond, Oklahoma, United States of America.
Fibrinolysis, the plasmin-mediated degradation of the fibrin mesh that stabilizes blood clots, is an important physiological process, and understanding mechanisms underlying lysis is critical for improved stroke treatment. Experimentalists are now able to study lysis on the scale of single fibrin fibers, but mathematical models of lysis continue to focus mostly on fibrin network degradation. Experiments have shown that while some degradation occurs along the length of a fiber, ultimately the fiber is cleaved at a single location.
View Article and Find Full Text PDFDependence of clot structure and fibrinolysis on apixaban and clotting activator.
Res Pract Thromb Haemost
November 2024
Department of Biomedical Engineering, Rutgers University, Piscataway, New Jersey, USA.
Background: Anticoagulants prevent the formation of potentially fatal blood clots. Apixaban is a direct oral anticoagulant that inhibits factor (F)Xa, thereby impeding the conversion of prothrombin into thrombin and the formation of blood clots. Blood clots are held together by fibrin networks that must be broken down (fibrinolysis) to restore blood flow.
View Article and Find Full Text PDFNovel Deep Sea Isoindole Alkaloid FGFC1 Exhibits Its Fibrinolytic Effects by Inhibiting Thrombin-Activatable Fibrinolysis Inhibitor.
Pharmaceuticals (Basel)
October 2024
Department of Marine Bio-Pharmacology, College of Food Science and Technology, Shanghai Ocean University, Shanghai 201306, China.
Background: The thrombin-activatable fibrinolysis inhibitor (TAFI) is an important regulator in the balance between blood clot formation (coagulation) and dissolution (fibrinolysis), which is mainly activated by thrombin bonded with thrombomodulin (TM).
Methods: In this study, the investigation focused on the unique target TAFI of fungi fibrinolytic compound 1 (FGFC1), a novel fibrinolytic compound sourced from the deep sea. In this sense, the regulation of TAFI by FGFC1, in comparison to established TAFI inhibitors such as DS-1040 and PCTI in hPPP, was investigated, which was validated through the molecular docking of FGFC1 to TAFI.
Associations of Circulating ANGPTL3, C-Terminal Domain-Containing ANGPTL4, and ANGPTL3/8 and ANGPTL4/8 Complexes with LPL Activity, Diabetes, Inflammation, and Cardiovascular Mortality.
Circulation
October 2024
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN (Y.Q.C., H.L., D.L., Y.W., E.Y.Z., Y.Q., R.J.K.).
Article Synopsis
- ANGPTL3/4/8 proteins regulate lipoprotein lipase (LPL) activity, with ANGPTL8 forming complexes that influence ANGPTL4's function; however, their association with cardiovascular outcomes is under-researched.
- This study involved measuring various ANGPTL proteins and complexes in two large population studies (LURIC and getABI) focusing on cardiovascular health and outcomes over several years.
- Findings showed that while ANGPTL3/8 inhibited LPL activity and correlated with increased LDL-C and triglycerides, they did not predict cardiovascular death; however, ANGPTL4/8 and CD-ANGPTL4 were linked to higher diabetes prevalence and increased cardiovascular mortality risk.
The influence of 4G/5G polymorphism in the plasminogen-activator-inhibitor-1 promoter on COVID-19 severity and endothelial dysfunction.
Front Immunol
September 2024
Department of Research Support Utilizing Bioresource Bank, Graduate School of Medicine, Juntendo University, Tokyo, Japan.
Article Synopsis
- PAI-1 is associated with blood clotting issues and endothelial dysfunction in severe COVID-19, and certain genetic variations can affect its expression.
- Clinical studies on COVID-19 patients found that while comorbidities didn’t correlate with specific genotypes, the 4G/5G polymorphism showed differences in fibrinolytic factors and IL-1β levels.
- The 4G4G genotype was linked to high PAI-1 levels and suppressed fibrinolysis, while inflammation-related endothelial dysfunction was a risk for those with the 5G5G genotype.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!